Drug class profile · refreshed daily from federal data

Cytoprotective Agent

2 molecules in this class, $1356 combined CY2024 Part D spend across 16 claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 14 Jul 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Cytoprotective Agent class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 2tracked in Part D
CY24 Part D spend: $1356combined across class
Total Rx claims: 16— unique beneficiaries
Generic mfrs (active): 8across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Bleomycin

Brand: Bleomycin · 16 Part D claims (CY24) · First FDA approval: 2000-04-10

4 generic mfrs Discontinued

Low NADAC$26.45

→

Avg plan cost$26.45

Part D spend $1356 1× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Dexrazoxane

— Part D claims (CY24) · First FDA approval: 2005-03-31

4 generic mfrs

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.